Ryan, K E <br/><br/>
Antithrombotic properties of dermatan sulphate (MF 701) in haemodialysis for chronic renal failure.  [electronic resource] 

 -  Thrombosis and haemostasis  Nov 1992 
 - 563-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0340-6245 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antithrombin III--metabolism<br/>Blood Coagulation--drug effects<br/>Dermatan Sulfate--administration & dosage<br/>Dose-Response Relationship, Drug<br/>Female<br/>Fibrinolytic Agents--therapeutic use<br/>Fibrinopeptide A--metabolism<br/>Heparin--therapeutic use<br/>Humans<br/>Kidney Failure, Chronic--blood<br/>Male<br/>Middle Aged<br/>Peptide Hydrolases--metabolism<br/>Renal Dialysis<br/>Thrombosis--prevention & control